Salicylic acid
Salicylic acid is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target acid-sensing ion channel 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 111medco 2% salicylic acid cleansing bar | C200263 | 2023-12-12 |
| 24 alopecia reliefshampoo | unapproved drug other | 2020-08-08 |
| 28.5% salicylic acid | unapproved drug other | 2018-04-06 |
| 3 in 1 cleanser | OTC monograph final | 2020-09-16 |
| 3-1 acne treatment pads | C200263 | 2024-10-09 |
| 30 day acne treatment kit | C200263 | 2024-11-04 |
| 45% urea cream 2% salicylic acid | C200263 | 2024-11-08 |
| aavrani dry scalp rescue serum | C200263 | 2023-10-25 |
| ac out spot stop serum | unapproved drug other | 2012-09-25 |
| acence tea tree tock blemish spot | OTC monograph final | 2016-01-22 |
Show 1439 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AE: Other antifungals for topical use in atc
— D01AE12: Salicylic acid
— D02: Emollients and protectives
— D02A: Emollients and protectives
— D02AF: Salicylic acid emollient and protective preparations
M: Musculo-skeletal system drugs
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AC: Preparations with salicylic acid derivatives, topical for joint and muscle pain
N: Nervous system drugs
— N02: Analgesics
— N02B: Other analgesics and antipyretics in atc
— N02BA: Salicylic acid and derivatives, analgesics and antipyretics
P: Antiparasitic products, insecticides and repellents
— P02: Anthelmintics
— P02D: Anticestodals
— P02DA: Salicylic acid derivative anticestodals
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BC: Antiinflammatory agents, non-steroidal, ophthalmologic
— S01BC08: Salicylic acid
HCPCS
No data
Clinical
Clinical Trials
4542 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | 4 | 1 | 7 | 12 |
| Macular edema | D008269 | — | — | — | — | 1 | 1 | 3 | 5 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | 1 | — | 1 |
| Wound healing | D014945 | GO_0042060 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | 1 | — | — | 2 |
| Edema | D004487 | — | R60.9 | — | — | 1 | — | 1 | 2 |
| Photoallergic dermatitis | D017454 | — | L56.2 | — | — | 1 | — | 1 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | 2 | — | — | 2 |
| Dermatitis | D003872 | — | L30.9 | — | — | 1 | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | — | 1 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | 1 | — | — | — | — | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | — | H35.9 | — | — | — | — | 1 | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | — | 1 | 1 |
| Contraception | D003267 | — | — | — | — | — | — | 1 | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Endophthalmitis | D009877 | — | — | — | — | — | — | 1 | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Salicylic acid |
| INN | — |
| Description | Salicylic acid is a monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves. It has a role as an antiinfective agent, an antifungal agent, a keratolytic drug, an EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor, a plant metabolite, an algal metabolite and a plant hormone. It is a conjugate acid of a salicylate. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1ccccc1O |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Salicylic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Salicylic acid
+
Sulfur
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 267,483 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35,434 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use